Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ilypsa
Santa Clara / San Francisco Bay Area [1], California, United Statesilypsa.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ilypsa’s lead candidate, ILY101, completed Phase 2 trials for treating hyperphosphatemia in CKD patients on hemodialysis. The company also had a second program targeting hyperkalemia. After acquisition by Amgen, further development of the phosphorus-binding polymer was discontinued despite positive Phase 2 data[4].
- Therapeutic areas
- Nephrology
- Modalities
- Non-absorbed polymeric drugs (specifically phosphate and potassium binders)
- Industry
- Biotech
02
Partnerships
Saltigo/Lanxess for manufacturing active ingredients to FDA standards[4]Astellas Pharma licensed rights to ILY101 for Japan development[4]
Beyond the preview
Go deeper on Ilypsa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ilypsa.